Objectives Surgery and platinum-taxane doublet (PTD) chemotherapy are standard treatment for ovarian cancer (OC); adoption of maintenance therapies has been more limited. This analysis describes characteristics of OC patients and real-world treatment patterns.

Methods The Tempus dataset contains EMR data on U.S. oncology patients. This study included women with a primary diagnosis of OC; women treated with poly-ADP ribose polymerase inhibitors (PARPi), pembrolizumab, or nivolumab were excluded (n=288; final n=3,370). Descriptive statistics were calculated for patient characteristics, surgery/radiation/chemotherapy, and time from diagnosis to surgery.

Results Median age at diagnosis was 60, 55% of patients were advanced-stage and 36% were ECOG 0/1. 91% had surgery, 13% radiation, and 9% neither. Median time from diagnosis was approximately 7.5 months for most surgeries, but longer for omentectomy (16 months) and bowel resection (10 months). of patients receiving first-line (1L) chemotherapy (n=2,041), 96% received a platinum (71% PTD), 7% received bevacizumab (bev) + PTD, and 3% received bev maintenance. In second-line (2L), 48% received a platinum, 14% PTD, 6% PTD+bev, 6% bev maintenance, and 39% single-agent therapy. Patterns over time are shown in the table 1.

Conclusions Most OC patients received surgery and 2/3 received chemotherapy. PTD was the predominant 1L regimen, and in 2L platinum was used in nearly half of patients. Bev was the most used maintenance therapy for 2L, and use increased over time. Understanding these historical patterns helps inform stakeholders of the opportunity for PARPi and other advances in OC treatment.